Our case report recommended a promising targeted therapeutic option for patients with metastatic NSCLC with <i>LDLR-ROS1</i> fusion and highlighted the importance of genetic testing for accurate treatment. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.